Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Accumulated Expenses (2017 - 2022)

Historic Accumulated Expenses for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to $3.7 million.

  • Iterum Therapeutics' Accumulated Expenses rose 12082.84% to $3.7 million in Q3 2022 from the same period last year, while for Sep 2022 it was $3.7 million, marking a year-over-year increase of 12082.84%. This contributed to the annual value of $1.2 million for FY2021, which is 3630.4% down from last year.
  • As of Q3 2022, Iterum Therapeutics' Accumulated Expenses stood at $3.7 million, which was up 12082.84% from $3.0 million recorded in Q2 2022.
  • Over the past 5 years, Iterum Therapeutics' Accumulated Expenses peaked at $17.1 million during Q3 2019, and registered a low of $1.2 million during Q4 2021.
  • For the 5-year period, Iterum Therapeutics' Accumulated Expenses averaged around $5.4 million, with its median value being $3.8 million (2020).
  • Its Accumulated Expenses has fluctuated over the past 5 years, first skyrocketed by 23865.57% in 2019, then plummeted by 8693.21% in 2020.
  • Iterum Therapeutics' Accumulated Expenses (Quarter) stood at $7.0 million in 2018, then surged by 76.81% to $12.5 million in 2019, then crashed by 85.32% to $1.8 million in 2020, then crashed by 36.3% to $1.2 million in 2021, then soared by 220.34% to $3.7 million in 2022.
  • Its last three reported values are $3.7 million in Q3 2022, $3.0 million for Q2 2022, and $2.0 million during Q1 2022.